Areas where scientific evidence is lacking or incomplete.
Semax, Selank, Dihexa and Noopept have no multi-centre, powered randomised controlled trials in ADHD populations. Available human data is from adjacent indications (stroke, dementia, healthy volunteer cognition) or from open-label biohacker case series.
Implications: Every efficacy claim for these peptides in ADHD is an inference across populations. Magnitude of effect, response predictors, and non-responder rates in ADHD specifically are unknown. The protocol operates on mechanistic plausibility plus adjacent evidence, not primary indication evidence.
Chronic multi-year use of synthetic neuropeptides is essentially unstudied in humans. Dihexa's HGF/c-Met activation is the salient concrete concern — a theoretical oncogenic risk that cannot be excluded with existing data.
Implications: 'Safe for a cycle' and 'safe over years' are different questions, and current literature only supports the first. The protocol's cycling discipline (25–50% off-time, 2–3 cycles per year caps) is a risk-management heuristic in the absence of long-term data, not evidence of long-term safety.
There is effectively no data for Semax, Selank, Dihexa or Noopept in pediatric ADHD. Cerebrolysin has some pediatric literature but in very different indications (perinatal hypoxic-ischaemic encephalopathy, developmental delay), not ADHD.
Implications: The pediatric gap is severe enough that this protocol treats it as a hard contraindication. Off-label extension of adult peptide protocols to children is not supported by the data and risks developmental neurobiology effects that adult dosing literature cannot predict.
Very little is known about how Semax, Selank or Noopept interact with methylphenidate or amphetamine-class ADHD medications. Mechanistic speculation exists (dopaminergic vs neurotrophic axes) but formal interaction studies do not.
Implications: For the majority-case reader who is on or considering stimulants, the combination question is unanswered. Empirical caution (start peptide only while stimulant-stable, observe sleep and BP closely, stagger timing) is reasonable but is not a substitute for an interaction study.
Current Semax/Selank/Cerebrolysin dose ranges derive from Eastern European clinical trials in stroke and dementia or from biohacker self-report. ADHD-specific dose–response curves do not exist in peer-reviewed literature.
Implications: The 'Safe-Default' column in this protocol is conservative by construction — it lands below experimental biohacker ranges and within the lower half of the stroke/dementia dosing. But even 'conservative' here is an informed guess rather than a titration against ADHD-specific endpoints.
Framing these peptides as 'stimulant alternatives' is common in biohacking coverage, but no trial has compared Semax, Selank or Noopept against methylphenidate or amphetamine in ADHD endpoints.
Implications: Comparative claims ('as effective as', 'gentler than', 'cleaner than') are marketing, not data. The honest position is that these compounds work through different mechanisms, with different risk profiles, and may be complementary, substitutable, or inferior for a given patient — the trials to decide that have not been run.
Expert disagreements and competing evidence.
Dihexa is millions of times more potent than BDNF at inducing synaptogenesis, per Benoist et al. 2014.
2014 paper, since retracted; anecdotal self-report; preclinical activity in unrelated Harding-lab studies.
The Benoist et al. 2014 study underpinning that potency claim has been formally retracted.
PubMed retraction record; Athira Pharma LIFT-AD Phase 2/3 failure announcement late 2024 / early 2025; discontinuation for Alzheimer's indication.
Verdict Note
The retraction is documented and the human-translated derivative (fosgonimeton / ATH-1017) failed Phase 2/3 in Alzheimer's. The 'millions of times more potent' language still circulates in biohacking coverage but has no surviving authoritative source.
Epilepsy and status epilepticus are explicit contraindications for Cerebrolysin.
Cerebrolysin Treatment Handbook, Special Warnings section.
Seizures are not a contraindication; Cerebrolysin treatment can continue if a seizure occurs during therapy.
Cerebrolysin Treatment Handbook, clinical-scenarios section.
Verdict Note
The Cerebrolysin Treatment Handbook contains both statements in different sections. The operational read most clinicians adopt: status epilepticus is an absolute contraindication, controlled epilepsy is a caution-and-monitor, an incidental seizure during therapy is not necessarily a stop signal but requires re-evaluation.
Noopept is active at doses 1,000 times lower than piracetam.
Russian clinical pharmacology reviews; some Western secondary sources.
Effective Noopept doses are only approximately 3× lower than piracetam.
Rodent behavioural studies measuring memory and cognitive endpoints directly.
Verdict Note
The two claims appear in sources of comparable authority. The discrepancy likely reflects different endpoints (receptor binding vs behavioural outcome) and different rodent models. The operational implication is humility about the 'potent nootropic' framing — the potency multiplier is not settled.
Semax and Selank have 'no side effects' and are 'safe and highly effective' — per Russian clinical literature.
Russian institutional clinical trial and case-series publications.
Semax and Selank carry significant safety risks including immunogenicity; both are FDA Category 2 Bulk Drug Substances prohibited from compounding.
FDA Category 2 Bulk Drug Substance determinations.
Verdict Note
Both statements are partly true. The Russian clinical record is real — decades of use with favourable in-setting safety data. The FDA position is also real — insufficient data by US regulatory standards plus immunogenicity concerns on different populations. The honest synthesis is: favourable case-series evidence in Russian clinical use, insufficient to meet FDA pharmacovigilance and immunogenicity thresholds for population-scale approval.
Semax acts primarily through rapid elevation of BDNF protein and TrkB receptor phosphorylation.
Rodent and in-vitro studies showing ≈1.4× BDNF and ≈1.6× TrkB phosphorylation post-dose.
The mechanism of Semax is unknown or unclear; candidates include melanocortin receptor interaction and enkephalinase inhibition.
Pharmacology review literature citing melanocortin receptor affinity and enkephalinase inhibition as alternative candidate mechanisms.
Verdict Note
The BDNF/TrkB effect is measured and reproducible. Whether that is the primary mechanism of Semax's cognitive effect, an important secondary effect, or a downstream consequence of melanocortin or enkephalinase activity is not settled. The distinction matters for predicting which patients respond and what the long-term receptor-level effects are.
Conservative adult nutrient dosing: Citicoline 250–500 mg/day, Zinc 8–15 mg/day, Omega-3 1,000 mg EPA+DHA/day.
General cognitive-health literature and integrative-medicine guides.
Clinical-protocol nutrient dosing: Citicoline up to 1,000 mg/day, Zinc 25–50 mg/day (with copper balance), Omega-3 2,000+ mg/day.
Clinical protocol literature for deficiency-specific and therapeutic dosing.
Verdict Note
For ambulatory ADHD self-management without specific deficiency diagnosis, the conservative range is the better default. The higher clinical-protocol range is appropriate under supervision for diagnosed deficiency or therapeutic targeting (e.g. severe omega-3 deficiency, diagnosed zinc-responsive attention presentations). Default to the lower range and escalate with lab data, not with ambition.